GlassScriptPhysician profile
Nimesh N Patel
NPI 1194839753
$22,206.01
in general payments reported to CMS, 2019-2025
61 companies · $3,964 in 2025
The $3,964 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,334 · 2020: $2,162 · 2021: $5,006 · 2022: $3,042 · 2023: $2,668 · 2024: $3,031 · 2025: $3,964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,578 · Education: $84.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,577.88 |
| Education | $84.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,682.82 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $2,187.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,986.13 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $1,545.52 | 2020-2021 | |
| Lilly USA, LLC | $1,206.91 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $938.83 | 2019-2025 | Jardiance, Synjardy |
| Pfizer INC. | $761.43 | 2019-2025 | |
| Antares Pharma, INC. | $727.85 | 2020-2025 | Xyosted, Tlando, Nocdurna |
| Amarin Pharma, INC. | $661.92 | 2019-2022 | |
| Corium, LLC | $651.35 | 2021-2025 | Azstarys |
| Inspire Medical Systems, INC. | $636.96 | 2021-2024 | Inspire |
| Glaxosmithkline, LLC. | $630.54 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $628.13 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $548.98 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $501.69 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nimesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.